Form 8-K

8-K — IRIDEX CORP

Accession: 0001193125-26-126323

Filed: 2026-03-26

Period: 2026-03-26

CIK: 0001006045

SIC: 3845 (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — irix-20260326.htm (Primary)

EX-99.1 (irix-ex99_1.htm)

GRAPHIC (img156381773_0.jpg)

GRAPHIC (img156381773_1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: irix-20260326.htm · Sequence: 1

8-K

false000100604500010060452026-03-262026-03-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

March 26, 2026

(Date of Report (date of earliest event reported)

IRIDEX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

000-27598

77-0210467

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification Number)

1212 Terra Bella Avenue

Mountain View, California 94043

(Address of principal executive offices, including zip code)

(650) 940-4700

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of Class

Trading

Symbol

Name of Exchange on Which Registered

Common Stock, par value $0.01 per share

IRIX

Nasdaq Capital Market

Item 2.02. Results of Operations and Financial Condition.

On March 26, 2026, IRIDEX Corporation (the "Company") issued a press release discussing its financial results for its fourth fiscal quarter ended January 3, 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.

Description

99.1

Press Release dated March 26, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IRIDEX CORPORATION

By:

/s/ Romeo R. Dizon

Romeo R. Dizon

Chief Financial Officer

Date: March 26, 2026

-3-

EX-99.1

Filename: irix-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies

MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026.

Fourth Quarter 2025 Financial Highlights

•

Generated total revenue of $14.7 million, representing growth of 16% year-over-year compared to $12.7 million in the prior year quarter

•

Cyclo G6® product family revenue was $3.8 million, representing growth of 15% year-over-year compared to $3.3 million in the prior year quarter

Sold 15,900 Cyclo G6 probes compared to 13,300 in the prior year quarter

Sold 44 Cyclo G6 Glaucoma Laser Systems compared to 47 in the prior year quarter

•

Retina product revenue was $8.9 million, representing growth of 22% year-over-year

•

Reduced operating expenses by 10% compared to the prior year period

•

Cash and cash equivalents as of January 3, 2026 were $6.0 million, an increase of $0.4 million in the quarter.

Full Year 2025 Results

•

Generated total revenue of $52.7 million, compared to $48.7 million in 2024, representing growth of 8%

•

Cyclo G6® Glaucoma product family revenue of $13.8 million, compared to $12.7 million in 2024

Sold 57,800 Cyclo G6® probes, compared to 55,400 in 2024

Sold 133 Cyclo G6® Glaucoma Laser Systems compared to 125 in 2024

•

Retina product revenue was $30.3 million, compared to $27.8 million in 2024

•

Reduced operating expenses by 22% compared to the prior year

“2025 was a transformational year for Iridex, we grew revenue, reduced operating expenses, and achieved positive adjusted EBITDA for the first time in recent company history,” said Patrick Mercer, President and CEO of Iridex. “I am proud to announce that our fourth quarter was our strongest of the year, with momentum across both our glaucoma and retina businesses driving cash flow positive operations. As we enter 2026, we have a growing installed base of systems, manufacturing efficiency initiatives underway and leaner cost structure, that position us to build on our 2025 progress and drive sustainable profitability.”

Fourth Quarter 2025 Financial Results

Revenue for the three months ended January 3, 2026 was $14.7 million, representing a 16% year-over-year increase compared to the fourth quarter of 2024. The increase in revenue was primarily driven by higher retina system sales, including Pascal sales, glaucoma probe sales and an extra selling week in the fiscal quarter. Total product revenue from the Cyclo G6 product family was $3.8 million, representing growth of 15% year-over-year compared to $3.3 million in the prior year quarter. Other revenue decreased $0.1 million to $2.0 million.

Gross profit in the fourth quarter of 2025 was $5.5 million or a 37% gross margin, a decrease of $0.1 million compared to $5.6 million, or a 44.0% gross margin, in the prior year period. Gross margin decreased primarily due to increase in overall manufacturing costs, including increased product costs associated with tariff developments throughout the year, and lower capitalization of manufacturing overhead as inventory levels declined.

Operating expenses were $5.5 million in Q4 2025, a decrease of $0.6 million, or 10% compared to $6.1 million in Q4 2024, due mainly to expense reduction measures taken in late 2024.

Net loss was $0.2 million or $0.01 per share for Q4 2025, compared to a net loss of $0.8 million, or $0.05 per share, in the same period of the prior year.

Non-GAAP adjusted EBITDA for Q4 2025 was $0.8 million, an improvement of $0.2 million, compared to Non-GAAP adjusted EBITDA of $0.6 million for Q4 2024.

Cash and cash equivalents as of January 3, 2026 were $6.0 million, an increase of $0.4 million in the quarter.

Full Year 2025 Financial Results

Revenue for the year ended January 3, 2026 was $52.7 million, representing growth of 8% compared to $48.7 million in 2024. The increase in revenue was primarily driven by higher retina system sales, including Pascal sales, glaucoma probe sales and an extra selling week in the fiscal year. Retina product revenue was $30.3 million compared to $27.8 million in the prior year, an increase of 9%, driven by higher capital system sales. Total product revenue from the Cyclo G6 glaucoma product family was $13.8 million compared to $12.7 million in fiscal year 2024, driven by higher capital system sales and probe utilization. Other revenue was $8.6 million in 2025 compared to $8.1 million in the prior year primarily driven by higher service revenue.

Gross profit for the full year 2025 was $19.2 million or a 37% gross margin, a decrease compared to $19.5 million, or a 40% gross margin in 2024. Gross margin decreased primarily due to inventory write-downs, increase in overall manufacturing costs, including increased product costs associated with tariff developments throughout the year, and lower capitalization of manufacturing overhead as inventory levels declined.

Operating expenses for 2025 decreased 22% to $21.8 million compared to $27.8 million in the prior year. The decrease in operating expenses was due to expense reduction measures implemented in the second half of 2024.

Net loss for 2025 improved to $4.4 million, or $0.26 per share, compared to a net loss of $8.9 million, or $0.54 per share in the prior year.

Total adjusted EBITDA for 2025 was $1.1 million, an improvement of $5.4 million, compared to adjusted EBITDA loss $4.3 million in 2024.

2026 Financial Outlook

The Company currently forecasts 2026 revenue of between $51 million and $53 million. This guidance contemplates the impact of market disruptions from the conflict in the Middle East, which are impacting

product delivery timelines. Considering these disruptions, the guidance contemplates no 2026 sales in the Middle East region. On a pro forma basis, adjusted to exclude Middle East revenue in 2025, guidance represents 2026 growth of 1% to 5% compared to 2025. For 2026 adjusted operating expenses, which exclude depreciation and amortization, and stock compensation, are expected to be in the range of $19 million to $19.5 million and the Company expects to generate positive operating cash flow in full year 2026.

Webcast and Conference Call Information

Iridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com or by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and providing Conference ID: 3693990.

About Iridex Corporation

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning financial forecasts, expectations for profitability, positive cash flow and financial and operating results in fiscal year 2026. The Company can provide no assurance that it will achieve or sustain profitability. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks further described in the “Risk Factors” section of Iridex’s most recent Annual Report on Form 10-K, as well as in Iridex’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Management evaluates and makes operating decisions using various performance measures. In addition to Iridex’s GAAP results, we consider Adjusted EBITDA. This

non-GAAP result should not be considered as an alternative to net income, net cash provided by operating activities, or any other performance measure derived in accordance with GAAP. We present this non-GAAP result because management considers it to be an important supplemental measure of Iridex’s performance and refers to such measures when analyzing Iridex’s strategy and operations.

In calculating the above non-GAAP result: Adjusted EBITDA is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Adjusted EBITDA exclude from their GAAP equivalents items listed below;

•

Share-based compensation expense. We excluded from our non-GAAP results the expense related to equity-based compensation plans as it represents expenses that do not require cash settlement from Iridex.

•

Severance-related expenses. We excluded from our non-GAAP results the expenses related to restructuring events, partially offset by reversals of previously recognized severance expenses in subsequent periods. These expenses are unrelated to our ongoing operations, vary in size and frequency and are subject to significant fluctuations from period to period due to varying levels of restructuring activity. We believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.

•

Nasdaq listing requirements compliance plan expenses. We excluded from our non-GAAP results the expenses related to plans for regaining compliance with the Nasdaq listing requirements. These expenses are unrelated to our ongoing operations, and we believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.

•

Loss on write-down of inventory. We excluded from our non-GAAP results the expenses related to the write down of inventory related to the transfer of production of several products to 3rd party contract manufacturers. In these types of transactions, not all applicable inventories are acquired by the contract manufacturers and thus, such inventory becomes excess and obsolete. These expenses are unrelated to our ongoing operations, and we believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.

Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock compensation plans or other items.

A detailed reconciliation between Iridex’s non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release as well as in Iridex’s other reports filed with or furnished to the SEC.

Investor Relations Contact

Philip Taylor

Gilmartin Group

investors@iridex.com

IRIDEX Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

Three Months Ended

Twelve Months Ended

January 3, 2026

December 28, 2024

January 3, 2026

December 28, 2024

Total revenues

14,724

12,696

52,675

48,669

Cost of revenues

9,247

7,110

33,448

29,167

Gross profit

5,477

5,586

19,227

19,502

Operating expenses:

Research and development

949

1,113

3,668

5,449

Sales and marketing

2,751

2,700

10,396

12,579

General and administrative

1,792

2,275

7,734

9,776

Total operating expenses

5,492

6,088

21,798

27,804

Loss from operations

(15

)

(502

)

(2,571

)

(8,302

)

Other income (expense), net

(149

)

(338

)

(1,809

)

(540

)

Loss from operations before provision for income taxes

(164

)

(840

)

(4,380

)

(8,842

)

Provision for income taxes

)

Net loss

(184

)

(834

)

(4,437

)

(8,910

)

Net loss per share:

Basic

(0.01

)

(0.05

)

(0.26

)

(0.54

)

Diluted

(0.01

)

(0.05

)

(0.26

)

(0.54

)

Weighted average shares used in computing net loss per common share:

Basic

17,187

16,636

16,934

16,439

Diluted

17,187

16,636

16,934

16,439

IRIDEX Corporation

Condensed Consolidated Balance Sheets

(In thousands)

January 3, 2026

December 28, 2024

ASSETS

Current assets:

Cash and cash equivalents

6,028

2,387

Accounts receivable, net

9,545

8,394

Inventories

7,877

10,817

Prepaid expenses and other current assets

1,802

1,964

Total current assets

25,252

23,562

Property and equipment, net

115

Intangible assets, net

984

1,307

Goodwill

965

Operating lease right-of-use assets, net

768

1,792

Other long-term assets

1,124

1,394

Total assets

29,151

29,135

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

5,502

7,594

Accrued compensation

2,340

1,672

Accrued expenses

608

477

Convertible note payable, current

1,734

Other current liabilities

1,899

1,812

Deferred revenue, current

2,160

2,176

Operating lease liabilities, current

699

1,094

Total current liabilities

13,208

16,559

Long-term liabilities:

Deferred revenue

6,801

8,350

Operating lease liabilities

811

Convertible note payable

3,735

1,004

Other long-term liabilities

387

314

Total liabilities

24,229

27,038

Stockholders’ equity:

Series B convertible preferred stock

6,000

Common stock

174

Additional paid-in capital

91,208

89,881

Accumulated other comprehensive income (loss)

(14

)

Accumulated deficit

(92,446

)

(88,009

)

Total stockholders’ equity

4,922

2,097

Total liabilities and stockholders’ equity

29,151

29,135

IRIDEX Corporation

Reconciliation of GAAP Net Loss to Adjusted EBITDA

(In thousands)

Three Months Ended

Twelve Months Ended

January 3, 2026

December 28, 2024

January 3, 2026

December 28, 2024

Reconciliation of GAAP net loss to Adjusted EBITDA(a)

GAAP net loss

(184

)

(834

)

(4,437

)

(8,910

)

Interest (income) expense, net

)

269

(38

)

256

Other expense, net

156

1,847

283

Provision (benefit from) for income taxes

)

Nasdaq listing compliance

—

152

—

Depreciation and amortization

422

377

1,547

1,424

Inventory write-down

—

823

—

Stock-based compensation

213

316

775

1,243

Severance related expense (for head count reduction)

197

421

396

729

Strategic process legal expenses

—

633

Adjusted EBITDA

817

611

1,122

(4,274

)

(a)Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share- based compensation, as well as certain non-GAAP adjustments.

GRAPHIC

Filename: img156381773_0.jpg · Sequence: 3

Binary file (14713 bytes)

Download img156381773_0.jpg

GRAPHIC

Filename: img156381773_1.jpg · Sequence: 4

Binary file (9950 bytes)

Download img156381773_1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Document and Entity Information

Mar. 26, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 26, 2026

Entity Registrant Name

IRIDEX CORPORATION

Entity Central Index Key

0001006045

Entity File Number

000-27598

Entity Incorporation, State or Country Code

Entity Tax Identification Number

77-0210467

Entity Address, Address Line One

1212 Terra Bella Avenue

Entity Address, City or Town

Mountain View

Entity Address, State or Province

Entity Address, Postal Zip Code

94043

City Area Code

650

Local Phone Number

940-4700

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.01 per share

Trading Symbol

IRIX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration